AzTrials
AzTrials

HypertensionCardio-RubusNCT02355444

Effects of Blackberry-derived Polyphenols on Cardiovascular Risk in Adults

A study testing blackberry polyphenol enriched beverage and blackberry beverage with minimal polyphenol concentrations in people with Hypertension, run by University College Cork at 1 site in Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cardiovascular disease (CVD) is the most common cause of death in Ireland, accounting for 33% of all deaths. Hypertension or elevated blood pressure, is also a significant health problem, however, it is one of the major controllable risk factors associated with CVD. Read more about this study

Who is it for?
Ages 45 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Hypertension
What is being tested?
blackberry polyphenol enriched beverage and blackberry beverage with minimal polyphenol concentrations
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
83 participants
Where
1 siteIreland
Study dates
May 2015to Oct 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adult Caucasian men and women (ratio men: women, 70:30)
  • Good general health
  • Systolic blood pressure: 130 - 149 mmHg
  • Body mass index (BMI): 25.0 - 35.0 kg/m2
  • Signed consent form

Who cannot join

  • Current smokers
  • Diagnosed hypertension
  • History of cardiovascular events such as stroke, myocardial infarction or peripheral vascular disease
  • Diagnosed medical illness including diabetes mellitus (Types 1 \& 2), chronic kidney disease and gastro-intestinal diseases
  • Medications that may affect any of the study outcome measures: anti-hypertensive medications and lipid lowering therapies e.g. statins.
  • Suspected hypersensitivity or allergy to berries.
  • Intolerance for aspirin or salicylate acid.
  • Current consumption of nutraceuticals, botanical extracts or other polyphenol-rich supplements.

Trial locations and contacts

1 site in 1 country.

Ireland1 site
  • Human Nutrition Studies Unit, School of Food & Nutritional Sciences, UCC

    Cork, Cork

Other trials in Ireland

About this study

Official title: Dietary Intervention to Investigate the Effects of Blackberry-derived Polyphenols on Cardio-metabolic Risk Factors in Adults

Cardiovascular disease (CVD) is the most common cause of death in Ireland, accounting for 33% of all deaths. Hypertension or elevated blood pressure, is also a significant health problem, however, it is one of the major controllable risk factors associated with CVD. While increased consumption of fruit and vegetables is associated with reduced risk of CVD, evidence is accumulating that consumption of berry fruits in particular, may promote cardiovascular health. Blackberries have a favourable nutritional profile, in that they are rich in dietary fibre, vitamins C, K and folate but low in dietary fat and kilocalories. In addition, blackberries are a rich source of antioxidants, and contain numerous phytochemicals including polyphenols. The aim of this study is to investigate the potential beneficial effects of blackberry consumption on cardiovascular health, in particular, effects on blood pressure.

Read the detailed description

Dietary factors play a significant role in the prevention and/or treatment of hypertension and significant efforts are being put in to the development of functional foods with antihypertensive activity. Blackberries and their intrinsic polyphenols, consumed as part of a healthy diet, may be of functional interest in both the treatment and prevention of hypertension and dyslipidaemia. The Cardio-Rubus study presents healthy adults with an opportunity to participate in a human nutrition study that will assist in identifying biological effects of blackberry-derived components establishing further the value of berries as a nutritious, health conducive food.

It is proposed to carry out a crossover, randomized double-blind 18-week supplementation study in 100 men and women aged 45-70 years with a systolic blood pressure of 130-149 mmHg but who are otherwise in good health. The proposed sample size is based on systolic blood pressure data derived from baseline values of 700 adults who participated in RCTs that we have conducted at UCC over the last 6-7 years. The calculation for sample size is based on observational data of systolic blood pressure in older pre-hypertensive adults, which showed a mean (SD) SBP of 135 (3) mmHg. The proposed study is powered to detect a mean drop of 2 mmHg systolic blood pressure at 85% power and with a significance level of 5%. The calculations support the recruitment of 100 participants in total (n = 41 per group, rounded up to 50 to account for a 20% attrition rate).

Potential study participants will be recruited by researchers at the School of Food \& Nutritional Sciences and all study visits will take place at the Human Nutrition Studies Unit, UCC. In addition to the provision of written information, the study protocol will be clearly and comprehensively discussed with each potential participant prior to enrollment and their provision of informed written consent. Participants will initially complete a 2-week run in period which involves refraining from the consumption of specified foods items (predominantly berries and other fruits) until the end of the study. Each participant will be randomly assigned to receive one of two beverages (either a high dose or low dose blackberry polyphenol enriched beverage) for a period of 6-weeks (study phase 1) and then after a 2-week wash-out, the participant will receive the opposite treatment to that which was provided during study phase 1 for the next 6-weeks (study phase 2). After completion of study phase 2 there will be a 2-week wash-out followed by a final visit to UCC. Thus, after screening and enrolment on to the study, there will be a further 5 visits to UCC (at the baseline and endpoint of each study phase and at the end of the final washout phase). All 5 visits will be fasting morning visits where the nurse will take a small blood sample which will be analysed for blood lipids, fasting glucose and biomarkers of endothelial function. Brachial and central blood pressure will be measured as well as an assessment of arterial stiffness by pulse wave velocity analysis. Body weight, BMI and waist circumference will also be measured. Each participant's body composition (% body fat \& lean mass) will be assessed by DXA scan.

All information collected is strictly confidential. Samples and questionnaires will be labelled with a unique identifying code, and participant's names will not be used at any stage during data collection, database construction or data analysis. Data will be archived by the principal investigator. In any publications or other documents, participants will not be identified by name or code numbers. Group summary data will be presented in place of individual data, further ensuring confidentiality.

Conditions
Hypertension
Being tested
blackberry polyphenol enriched beverage, blackberry beverage with minimal polyphenol concentrations
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • blackberry polyphenol enriched beverageDietary supplement

    Also called Rubus Fructicosus

    Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.

  • blackberry beverage with minimal polyphenol concentrationsDietary supplement

    Also called Rubus Fructicosus

    Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.

Study groups in NCT02355444
Study groupRoleWhat they receive
High-dose blackberry polyphenol beverageExperimentalEach participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
Receives: Dietary Supplement: blackberry polyphenol enriched beverage
Low-dose blackberry polyphenol beveragePlacebo comparatorEach participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
Receives: Dietary Supplement: blackberry beverage with minimal polyphenol concentrations

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood Pressure

    A change between baseline blood pressure and endpoint blood pressure within the intervention group versus the control group.

    Measured: 42 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2015 (estimated)
  2. Study startMay 2015
  3. Primary completionOct 2016
  4. Study completionOct 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
83 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02355444
Sponsor's protocol ID
Cardio-rubus 13F539
Acronym
Cardio-Rubus
Status last verified
Feb 2017
First submitted
30 Jan 2015
Last updated
27 Feb 2017
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing blackberry polyphenol enriched beverage and blackberry beverage with minimal polyphenol concentrations in people with Hypertension, run by University College Cork at 1 site in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood Pressure (time frame: 42 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2017; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in